(VIANEWS) – Shares of ImmunoGen (NASDAQ: IMGN) jumped by a staggering 27.45% in 21 sessions from $4.7 at 2022-09-29, to $5.99 at 12:41 EST on Thursday, after two sequential sessions in a row of gains. NASDAQ is sliding 0.82% to $10,881.22, following the last session’s downward trend.
ImmunoGen’s last close was $6.10, 21.49% under its 52-week high of $7.77.
ImmunoGen, Inc., is a biotech company in clinical stage. It develops ADC therapies for cancer. Mirvetuximab Soravtansine is an ADC which targets folate receptor alpha (FRa) and is currently in Phase III clinical trials. Pivekimab Sunirine is a CD123-targeting ADC and is currently in Phase II clinical trials to treat acute myeloid and blastic plasmacytoid cell neplasma. Preclinical programs for the company include IMGC936, an ADC co-developed with MacroGenics, Inc., and IMGN151, a anti-FRa product candidate. Collaborations include Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CymX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. ImmunoGen, Inc., was established in 1980 and has its headquarters in Waltham, Massachusetts.
Earnings per Share
ImmunoGen’s trailing 12 month EPS is $-0.25.
For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -100.96%.
ImmunoGen’s value is higher than its moving average for 50 days of $5.52, and much more than its moving average for 200 days of $5.08.
ImmunoGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.05%, a positive 1.28%, and a positive 3.22%.
ImmunoGen’s highest amplitude of average volatility was 1.12% (last week), 2.36% (last month), and 3.22% (last quarter).
More news about ImmunoGen (IMGN).